IP Library Granted Patent US 9,556,108
Granted Patent B2
US 9,556,108 · App. 14/796,069 · Granted Jan 31, 2017

Process for preparing substituted phenylalkanes

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,556,108
App. No.
14/796,069
Granted
Jan 31, 2017
Kind
B2
Abstract

The invention provides methods for preparing substituted phenylalkanes. In particular, the processes comprise reacting a phenyl boronic compound with an α-β unsaturated carbonyl-containing compound via an asymmetric 1,4-addition reaction. The processes may be useful in the synthesis of tapentadol.

Claims (35)

1. A process for preparing a compound of Formula (VI), the process comprising:

a) contacting a compound of Formula (I) with a compound of Formula (VIII) in the presence of a transition metal catalyst and a chiral ligand to form a compound of Formula (IX);

b) contacting the compound of Formula (IX) with a secondary amine having Formula (X) to form a compound of Formula (V); and

c) contacting the compound of Formula (V) with an O-dealkylating agent to form the compound of Formula (VI),

wherein:

R is alkyl or alkyl substituted with other than aryl;

R 1 is hydrogen, alkyl, or substituted alkyl;

R 2 is hydrocarbyl or substituted hydrocarbyl;

R 3 , R 4 , R 5 , and R 7 are independently hydrogen, OR 20 , NR 20 R 21 , SR 20 R 21 , halo, hydrocarbyl, or substituted hydrocarbyl;

R 8 is

 —O—(CR 13 R 14 ) n —O—, or trihalo;

R 10 and R 11 are independently hydrocarbyl, substituted hydrocarbyl, or R 10 and R 11 together may form a ring or ring system selected from carbocyclic, heterocyclic, aryl, heteroaryl, or combinations thereof;

R 12 is hydrocarbyl or substituted hydrocarbyl;

R 13 and R 14 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or boron containing moiety;

R 20 and R 21 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl; and

n is an integer of 1 or greater.

2. The process of claim 1 , wherein R 1 is hydrogen, alkyl, or substituted alkyl; R 2 is alkyl or substituted alkyl; R 3 , R 4 , R 5 , and R 7 are independently hydrogen, alkyl, substituted alkyl, hydroxyl, alkoxy, substituted alkoxy, aryl, substituted aryl, alkylaryl, or substituted alkylaryl; R 10 and R 11 are independently alkyl or substituted alkyl; and R 13 and R 14 are independently hydrogen, alkyl, aryl, or alkylaryl.

3. The process of claim 2 , wherein R 1 is C 1 -C 10 alkyl; R 2 is C 1 -C 10 alkyl; R 3 , R 4 , R 5 , and R 7 are hydrogen; and R 10 , R 11 and R 12 are C 1 -C 10 alkyl.

4. The process of claim 1 , wherein R is methyl; R 1 is hydrogen; R 2 is ethyl; each of R 3 , R 4 , R 5 , and R 7 is hydrogen; and R 10 , R 11 , and R 12 are methyl.

5. The process of claim 1 , wherein the compound of Formula (I), the compound of Formula (VIII), and the transition metal catalyst are present at a molar ratio of about 1:0.5:0.001 to about 1:2.0:0.05; and step (a) is conducted at a temperature from about −10° C. to about 80° C.

6. The process of claim 5 , wherein the transition metal catalyst is a transition metal complex chosen from a rhodium complex, a palladium complex, or a ruthenium complex; the chiral ligand is a bicyclic chiral diene; and the transition metal catalyst and the chiral ligand are present at a weight ratio of about 1:0.1 to about 1:10.

7. The process of claim 6 , wherein the compound of Formula (IX) is obtained with a diastereomeric excess of at least about 60%.

8. The process of claim 6 , wherein step (a) further comprises contact with an amine, the amine being secondary, tertiary, chiral, or achiral.

9. The process of claim 8 , wherein the compound of Formula (I) and the amine are present at a molar ratio of about 1:0.01 to about 1:1.0.

10. The process of claim 9 , further comprising contact with a proton acceptor.

11. The process of claim 10 , wherein the compound of Formula (I) and the proton acceptor are present at a molar ratio of about 1:0.01 to about 1:2.

12. The process of claim 11 , wherein the compound of Formula (IX) is obtained with a diastereomeric excess of at least about 70%.

13. The process of claim 1 , wherein the compound of Formula (IX) and the compound of Formula (X) are present at a molar ratio of about 1:0.5 to about 1:60; and step (b) is conducted at a temperature of about 0° C. to about 80° C.

14. The process of claim 13 , further comprising contact with a reducing agent.

15. The process of claim 14 , wherein the compound of Formula (IX) and the reducing agent are present at a weight ratio of about 1:0.3 to about 1:5.

16. The process of claim 1 , wherein the O-dealkylating agent and the compound of Formula (V) are present at weight ratio of about 1:1 to about 400:1; and step (c) is conducted at a temperature of about 50° C. to about 200° C.

17. The process of claim 1 , wherein the compound of Formula (I) is m-methoxyphenylboronic acid, 3-methoxyphenyl trifluoroborate, 3-methoxyphenylboronic acid pinacol ester, 3-methoxyphenylboronic ester, or is derived from 3-methoxyphenylboroxine; the compound of Formula (VIII) is trans-2-methyl-2-pentenal; the transition metal catalyst is [RhCl(C 2 H 4 ) 2 ] 2 ; the chiral ligand is (1S,4S)-2,5-diphenylbicyclo[2,2,2]octa-2,5-diene; the compound of Formula (X) is dimethylamine; the O-dealkylating agent is a hydrogen halide; and the compound of Formula (VI) is 3-[(1R,2R)-3-(dimethyamino)-1-ethyl-2-methylpropyl]phenol.

18. The process of claim 17 , wherein step (a) further comprises contact with an amine and, optionally, a proton acceptor; the amine being 4-methylmorpholine.

19. The process of claim 18 , wherein the compound of Formula (I), the compound of Formula (VII), the transition metal catalyst, the chiral ligand, the amine, and the optional proton acceptor are present at a molar ratio of 1:1.15:0.007:0.4:0.2; step (a) is conducted at a temperature of about 23° C. and under nitrogen; the compound of Formula (IX) and the compound of Formula (X) are present at a molar ratio of about 1:1; step (b) is conducted in the presence of a reducing agent, at a temperate of about 23° C., and under nitrogen; the O-dealkylating agent and the compound of Formula (V) are present at a weight ratio of about 26:1; and step (c) is conducted at a temperature of about 110° C. and under nitrogen.

20. The process of claim 19 , wherein the compound of Formula (VI) has a yield of at least about 30%.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 039237, FRAME 0147 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0902 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2016
From: LIAO, SUBO; MCCLURG, JOSEPH; TRAWICK, BOBBY
To: MALLINCKRODT LLC
Reel/Frame 040515/0326 →